PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
about
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasisPPARs and the cardiovascular systemThe liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in micePeroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in miceTranscriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes.Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue.Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability.Lack of association between adiponectin levels and atherosclerosis in mice.Insulin resistance and atherosclerosis.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Protection from Metabolic Dysregulation, Obesity, and Atherosclerosis by Citrus Flavonoids: Activation of Hepatic PGC1α-Mediated Fatty Acid Oxidation.PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with HypertriglyceridemiaActivation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.PPARs as therapeutic targets in cardiovascular disease.PPARα as a therapeutic target in inflammation-associated diseases.Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Metabolic enzymes dysregulation in heart failure: the prospective therapy.13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophagesA novel strategy for designing the selective PPAR agonist by the "sum of activity" model.Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia.PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia.Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice.
P2860
Q24541529-9D8B9919-2816-4889-B878-BABD20CB2DF9Q24642728-F2559EF5-23E9-4632-A7C5-01122D800CD1Q28472536-4B157118-9FA5-425C-900F-098EEA8340E7Q30513404-FE54E0B9-4C3E-495D-AF57-CDF4259FEEDAQ33325906-29D82E0E-7D4E-4CC5-8BBD-8D2944FBEB04Q33638451-E8263AF2-AA17-4EB5-B82E-04B6731ECBAEQ33913173-AF77B0F1-E841-4865-BA28-67F0CA49CA49Q33958420-D9F652A4-B72F-4BED-BA8A-A72C837A3EC2Q34698887-34749DC2-1156-4E34-9FE2-541C323B6CCCQ35636191-7944FA97-812F-44A4-A1E9-EDAD0E3C24DEQ36014621-C798FB51-185A-47BA-99BE-333E9AD9613AQ36360452-23056AD7-8423-429E-AE77-F2583345F159Q36580568-8AFD31F4-EBAB-4E50-A6B9-F42AB5E5CB74Q36668641-53BF2BAE-6981-466C-AE27-0792A8B8CC27Q36842486-EE4B6EF0-94F0-450D-92B7-4FA80796F1ABQ37012012-7C7617A3-18CB-4F70-A882-DF8C2DD0A0C0Q37583596-C9A85A3A-7BCF-4A76-A531-7C75A85E27DAQ37699483-4B98079A-61E0-4AD0-AD4E-A67175F85907Q37790384-166E1FEE-AA34-4886-9110-8755F1DB5886Q38038289-D0B05B88-540E-4F47-A3D6-55B92986BB08Q38623544-DF84A8BB-B027-483F-84E3-92D8294E42FFQ38674742-6473C749-38F3-4AB8-868F-B59BAC595EEAQ39011735-6C429FD0-54AE-448B-8D9D-A9B6DC341545Q39435368-5E4E224C-14D3-4DC5-B856-943FD49DE509Q42964673-9AABC7F2-1722-4CFD-AF1B-35A7DB3B4CA9Q46914500-72492B17-2725-4733-97C4-74BB8335DA97Q48527716-F28F4B3B-D8B0-4E76-9646-7B49F6C7E706Q49962888-D3810154-4757-4F2A-B162-F6597C1A396E
P2860
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@en
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@nl
type
label
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@en
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@nl
prefLabel
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@en
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@nl
P2093
P50
P921
P1476
PPARalpha, but not PPARgamma, ...... e model of mixed dyslipidemia.
@en
P2093
Catherine Fiévet
Gérard Torpier
Hafid Mezdour
Jean-Charles Fruchart
P304
P356
10.1161/01.ATV.0000175756.56818.EE
P407
P577
2005-06-30T00:00:00Z